Key Takeaways

• Pancreatic cancer is on the rise across the rich world

• Most treatments involve a mix of surgery and radiation, with long recovery times

• Oncosil targets cancerous cells and reduces the negative impact on surrounding tissues or organs

What is Oncosil? 

Why does it Matter? 

• The main surgical approaches used to treat pancreatic cancer are potentially curative and palliative. Potentially curative surgeries seek to treat pancreatic cancer by removing it from the patient's body while palliative attempts to relieve symptoms such as a blocked bile duct or bowel. When pancreatic cancer only spreads to nearby areas, tumours can be removed through surgery. However, complete removal is the best chance to cure pancreatic cancer as partial removal doesn’t help patients live longer. Surgery is only done if the cancer can be removed entirely. 
• Palliative surgery: When pancreatic cancer spreads to the blood cells, there are two forms of palliative care. These include stent placement where metal tubes (stents) are used to keep the bile duct open, often done during endoscopic retrograde cholangiopancreatography (ECRP).
• Bypass Operations: The flow of bile tends to be rerouted from the bile duct into the intestine, bypassing the pancreas completely. While this provides longer-lasting relief, they equally have longer recovery periods than stent replacements. 
• Chemotherapy: Chemotherapy drugs kill cancer cells, control their growth, or relieve disease-related symptoms, and before surgery, try to reduce the size of the pancreatic tumour that needs to be removed. 
• However, surgery to reduce the size of a tumour is first done in a process called neoadjuvant therapy. Neoadjuvant therapy represents a seismic shift in pancreatic cancer treatment. This approach, combining chemotherapy and/or radiation therapy before surgery, is designed to shrink pancreatic tumours, thereby increasing the likelihood of complete surgical removal.

Why is Oncosil Different